Stomach and Duodenum: Systematic Review and Meta-Analysis

Gan C.a· Wu X.a· Shen Y.a· Cao Z.b· Jing J.c· Pan W.a,b

Author affiliations

aZhejiang Chinese Medical University, Hangzhou, China
bDepartment of Gastroenterology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China
cZhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Received: July 25, 2022
Accepted: January 18, 2023
Published online: March 10, 2023

Number of Print Pages: 12
Number of Figures: 3
Number of Tables: 3

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Abstract

Background: Helicobacter pylori infection is strongly associated with gastric cancer. However, there is currently no consensus on the association between H. pylori and gastric cancer prognosis. Methods: A systematic search was conducted on studies in PubMed, EMBASE, and Web of Science up to March 10, 2022. The quality of all included studies was assessed using the Newcastle-Ottawa Scale. The hazard ratio (HR) and its 95% confidence interval (95% CI) were extracted to analyze the association between H. pylori infection and prognosis of gastric cancer. In addition, subgroup analysis and publication bias were performed. Results: A total of 21 studies were involved. The pooled HR was 0.67 (95% CI, 0.56–0.79) for overall survival (OS) in H. pylori-positive patients, with the control (HR = 1) being the H. pylori-negative group. In the subgroup analysis, the pooled HR was 0.38 (95% CI, 0.24–0.59) for OS in H. pylori-positive patients who received surgery combined with chemotherapy. The pooled HR for disease-free survival was 0.74 (95% CI, 0.63–0.8) and 0.41 (95% CI, 0.26–0.65) in patients who received surgery combined with chemotherapy. Conclusion: H. pylori-positive gastric cancer patients have a better overall prognosis than H. pylori-negative patients. H. pylori infection has improved the prognosis of patients undergoing surgery or chemotherapy, among which the improvement was most obvious in patients undergoing surgery combined with chemotherapy.

© 2023 S. Karger AG, Basel

References Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–49. Fornaro L, Vasile E, Aprile G, Goetze TO, Vivaldi C, Falcone A, et al. Locally advanced gastro-oesophageal cancer: recent therapeutic advances and research directions. Cancer Treat Rev. 2018 Sep;69:90–100. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(Suppl 5):v38–49. Rausei S, Lianos GD. Treatment of gastric cancer. Cancers. 2020 Sep 15;12(9):2627. Ito N, Tsujimoto H, Ueno H, Xie Q, Shinomiya N. Helicobacter pylori-mediated immunity and signaling transduction in gastric cancer. J Clin Med. 2020 Nov 18;9(11):3699. Alipour M. Molecular mechanism of Helicobacter pylori-induced gastric cancer. J Gastrointest Cancer. 2021 Mar;52(1):23–30. Wang F, Sun G, Zou Y, Zhong F, Ma T, Li X. Protective role of Helicobacter pylori infection in prognosis of gastric cancer: evidence from 2,454 patients with gastric cancer. PLoS One. 2013 May 7;8(5):e62440. Fang X, Liu K, Cai J, Luo F, Yuan F, Chen P. Positive Helicobacter pylori status is associated with better overall survival for gastric cancer patients: evidence from case-cohort studies. Oncotarget. 2017 Oct 3;8(45):79604–17. Jia Z, Zheng M, Jiang J, Cao D, Wu Y, Zhang Y, et al. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis. Bmc Cancer. 2022 Feb 8;22(1):155. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007 Jun 7. 8: 16. Lee WJ, Lin JT, Shun CT, Lee WC, Yu SC, Lee PH, et al. Comparison between resectable gastric adenocarcinomas seropositive and seronegative for Helicobacter pylori. Br J Surg. 1995;82(6):802–5. Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7(3):211–22. Marrelli D, Pedrazzani C, Berardi A, Corso G, Neri A, Garosi L, et al. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer. 2009 May 15;115(10):2071–80. Qiu HB, Zhang LY, Keshari RP, Wang GQ, Zhou ZW, Xu DZ, et al. Relationship between H.Pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer. 2010 Jul 17;10(1):374. Gan L, Zhang X, Pan J, Liu K, Li P, Wang X, et al. Helicobacter pylori infection status as a prognostic indicator for gastric cancer. Acad J Second Mil Med Univ. 2011;32(12):1300–5. Santos RS, Lourenço JE, Herbella FA, del Grande JC, Patti MG. Helicobacter pylori has no influence on distal gastric cancer survival. Arq Gastroenterol. 2011;48(2):109–11. Choi IK, Sung HJ, Lee J-H, Kim JS, Seo JH. The relationship between Helicobacter pylori infection and the effects of chemotherapy in patients with advanced or metastatic gastric cancer. Cancer Chemother Pharmacol. 2012 Oct;70(4):555–8. Hur H, Lee SR, Xuan Y, Kim YB, Lim YA, Cho YK, et al. The Effects of Helicobacter pylori on the prognosis of patients with curatively resected gastric cancers in a population with high infection rate. J Korean Surg Soc. 2012 Oct;83(4):203–11. Kang SY, Han JH, Ahn MS, Lee HW, Jeong SH, Park JS, et al. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer. 2012 Feb 15;130(4):948–58. Li G, Wang Z, Wang Z, Xu J, Cui J, Cai S, et al. Gastric cancer patients with Helicobacter pylori infection have a poor prognosis. J Surg Oncol. 2013 Dec;108(7):421–6. Wang F, Sun GP, Zou YF, Zhong F, Ma T, Li XQ, et al. Helicobacter pylori infection predicts favorable outcome in patients with gastric cancer. Curr Oncol. 2013 Oct;20(5):e388–95. Posteraro B, Persiani R, Dall’Armi V, Biondi A, Arzani D, Sicoli F, et al. Prognostic factors and outcomes in Italian patients undergoing curative gastric cancer surgery. Eur J Surg Oncol. 2014 Mar;40(3):345–51. Postlewait LM, Squires MHIII, Kooby DA, Poultsides GA, Weber SM, Bloomston M, et al. Preoperative Helicobacter pylori infection is associated with increased survival after resection of gastric adenocarcinoma. Ann Surg Oncol. 2016 Apr;23(4):1225–33. Jung DH, Lee YC, Kim JH, Chung H, Park JC, Shin SK, et al. Postoperative Helicobacter pylori infection as a prognostic factor for gastric cancer patients after curative resection. Gut Liver. 2017 Sep;11(5):635–41. Kolb JM, Ozbek U, Harpaz N, Holcombe RF, Ang C. Effect of Helicobacter pylori infection on outcomes in resected gastric and gastroesophageal junction cancer. J Gastrointest Oncol. 2017;8(3):583–8. Tsai KF, Liou JM, Chen MJ, Chen CC, Kuo SH, Lai IR, et al. Distinct clinicopathological features and prognosis of Helicobacter pylori negative gastric cancer. PLoS One. 2017 Feb 2;12(2):e0170942. Nishizuka SS, Tamura G, Nakatochi M, Fukushima N, Ohmori Y, Sumida C, et al. Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy. J Surg Oncol. 2018 Apr 1;117(5):947–56. Fang WL, Huang KH, Chang SC, Lin CH, Chen MH, Chao Y, et al. Comparison of the clinicopathological characteristics and genetic alterations between patients with gastric cancer with or without Helicobacter pylori infection. Oncologist. 2019 Sep;24(9):e845–53. Kayapinar AK, Solakoglu D, Bas K, Oymaci E, Isbilen B, Calik B, et al. Relationship of prognostic factors in stomach cancer with helicobacter pylori: a retrospective study. Acta Gastroenterol Belg. 2021 Oct-Dec;84(4):607–17. Koizumi Y, Ahmad S, Ikeda M, Yashima-Abo A, Espina G, Sugimoto R, et al. Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with S-1 adjuvant chemotherapy. medRxiv. 2022;114(8):1149–58. Li G, Yu S, Xu J, Zhang X, Ye J, Wang Z, et al. The prognostic role of Helicobacter pylori in gastric cancer patients: a meta-analysis. Clin Res Hepatol Gastroenterol. 2019 Apr;43(2):216–24. Zepeda-Najar C, Palacios-Astudillo RX, Chávez-Hernández JD, Lino-Silva LS, Salcedo-Hernández RA. Prognostic impact of microsatellite instability in gastric cancer. Contemp Oncol. 2021;25(1):68–71. Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018 Feb;105(3):159–67. Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018 Nov;75(22):4151–62. Callery MP. Helicobacter pylori in gastric cancer: friend or foe?Gastroenterology. 2006 Sep;131(3):966–7. Algood HMS. T cell cytokines impact epithelial cell responses during Helicobacter pylori infection. J Immunol. 2020 Mar 15;204(6):1421–8. Valle JK, Kekki M, Sipponen P, Ihamäki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol. 1996 Jun;31(6):546–50. Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, et al. Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS. 2003 Jun;111(6):619–24. Kishikawa H, Ojiro K, Nakamura K, Katayama T, Arahata K, Takarabe S, et al. Previous Helicobacter pylori infection-induced atrophic gastritis: a distinct disease entity in an understudied population without a history of eradication. Helicobacter. 2020 Feb;25(1):e12669. Adachi K, Kishi K, Notsu T, Mishiro T, Sota K, Ishimura N, et al. Serum Anti-[]Helicobacter pylori[][] IgG antibody titer in []H. pylori[][]-negative cases with a different gastric mucosal atrophy status. Intern Med. 2020 Nov 15;59(22):2817–23. Wroblewski LE, Peek RMJr. Helicobacter pylori, cancer, and the gastric microbiota. Adv Exp Med Biol. 2016;908:393–408. Craanen ME, Blok P, Dekker W, Ferwerda J, Tytgat GN. Subtypes of intestinal metaplasia and Helicobacter pylori. Gut. 1992 May. 33(5):597–600. Genta RM, Gürer IE, Graham DY, Krishnan B, Segura AM, Gutierrez O, et al. Adherence of Helicobacter pylori to areas of incomplete intestinal metaplasia in the gastric mucosa. Gastroenterology. 1996 Nov;111(5):1206–11. Kang HY, Kim N, Park YS, Hwang JH, Kim JW, Jeong SH, et al. Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa. Dig Dis Sci. 2006 Dec;51(12):2310–5. Sáenz JB, Vargas N, Mills JC. Tropism for spasmolytic polypeptide-expressing metaplasia allows Helicobacter pylori to expand its intragastric niche. Gastroenterology. 2019 Jan;156(1):160–74. e7. Shimizu T, Choi E, Petersen CP, Noto JM, Romero-Gallo J, Piazuelo MB, et al. Characterization of progressive metaplasia in the gastric corpus mucosa of Mongolian gerbils infected with Helicobacter pylori. J Pathol. 2016 Aug;239(4):399–410. Hobsley M, Tovey FI, Holton J. Helicobacter pylori and gastric cancer: neither friend nor foe. Gastroenterology. 2007 May;132(5):2076. Liatsos C, Papaefthymiou A, Kyriakos N, Galanopoulos M, Doulberis M, Giakoumis M, et al. Helicobacter pylori, gastric microbiota and gastric cancer relationship: unrolling the tangle. World J Gastrointest Oncol. 2022 May 15. 14(5): 959–72. Iino C, Shimoyama T, Chinda D, Arai T, Chiba D, Nakaji S, et al. Infection of Helicobacter pylori and atrophic gastritis influence Lactobacillus in gut microbiota in a Japanese population. Front Immunol. 2018;9:712. Iino C, Shimoyama T, Chinda D, Sakuraba H, Fukuda S, Nakaji S. Influence of Helicobacter pylori infection and atrophic gastritis on the gut microbiota in a Japanese population. Digestion. 2020;101(4):422–32. Zi M, Zhang Y, Hu C, Zhang S, Chen J, Yuan L, et al. A literature review on the potential clinical implications of streptococci in gastric cancer. Front Microbiol. 2022;13:1010465. Waskito LA, Rezkitha YA, Vilaichone RK, Sugihartono T, Mustika S, Dewa Nyoman Wibawa I, et al. The role of non-Helicobacter pylori bacteria in the pathogenesis of gastroduodenal diseases. Gut Pathog. 2022 May 23;14(1):19. Zhou X, Su J, Zhu L, Zhang G. Helicobacter pylori modulates cisplatin sensitivity in gastric cancer by down-regulating miR-141 expression. Helicobacter. 2014 Jun;19(3):174–81. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Jama. 2010 May 5;303(17):1729–37. Cao J, Qi F, Liu T. Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis. Scand J Gastroenterol. 2014 Jun;49(6):690–704. Ter Veer E, Mohammad NH, Lodder P, Ngai LL, Samaan M, van Oijen MGH, et al. The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2016 Jul;19(3):696–712. Caruso ML, Fucci L. Histological identification of Helicobacter pylori in early and advanced gastric cancer. J Clin Gastroenterol. 1990 Oct;12(5):601–2. Tang YL, Gan RL, Dong BH, Jiang RC, Tang RJ. Detection and location of Helicobacter pylori in human gastric carcinomas. World J Gastroenterol. 2005 Mar 7;11(9):1387–91. Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol. 2007 Aug. 102(8):1789–98. Wang J, Liu X. Correlation analysis between Helicobacter pylori infection status and tumor clinical pathology as well as prognosis of gastric cancer patients. Iran J Public Health. 2018 Oct;47(10):1529–36. Kurtenkov O, Klaamas K, Sergeyev B, Chuzmarov V, Miljukhina L, Shljapnikova L. Better survival of Helicobacter pylori infected patients with early gastric cancer is related to a higher level of Thomsen-Friedenreich antigen-specific antibodies. Immunol Invest. 2003 Feb;32(1–2):83–93. Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, et al. Diagnosis of Helicobacter pylori infection: current options and developments. World J Gastroenterol. 2015 Oct 28. 21(40):11221–35. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection--the Maastricht IV/florence consensus Report. Gut. 2012 May;61(5):646–64. Article / Publication Details

Received: July 25, 2022
Accepted: January 18, 2023
Published online: March 10, 2023

Number of Print Pages: 12
Number of Figures: 3
Number of Tables: 3

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.